Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 15/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.41 |
| ▸ | PTPRF | P10586 | 3/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPRA | P18433 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539997 | 0.78 | KDM4E (0.50) | PTPN1PTPN2PTPRFPTPRBPTPN6 | |
| SCHEMBL7540301 | 0.76 | PTPN1 (0.44) | PTPN1PTPN2PTPRBPTPN6PTPRA | |
| SCHEMBL25192399 | 0.72 | HSD17B10 (0.48) | — | |
| SCHEMBL30500276 | 0.72 | HSD17B10 (0.48) | — | |
| SCHEMBL7536163 | 0.72 | PTPN1 (0.36) | PTPN1PTPN2PTPRFPTPRAKDM4E | |
| SCHEMBL19876095 | 0.71 | KDM4E (0.36) | PTPN1PTPN2KDM4EALDH1A1 | |
| SCHEMBL1698022 | 0.71 | IKBKB (0.42) | KDM4EALDH1A1HTT | |
| SCHEMBL14302410 | 0.66 | TP53 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL9212252 | 0.65 | HTT (0.62) | KDM4EALDH1A1HTT | |
| SCHEMBL9541072 | 0.63 | KDM4E (0.50) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002506073-A | — | — | 2002-02-26 | — | — | JP | claimed |
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-02-14 | — | — | US | claimed |
| EP-1062218-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | claimed |
| WO-1999046268-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | claimed |
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | PTPRCAP, PTPRS, PTPRA | PTPN1 7/4885PTPN2 9/4885PTPRF 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.